Nektar Therapeutics (LON:0UNL)
62.19
+0.91 (1.49%)
At close: Oct 20, 2025
Nektar Therapeutics Revenue
Nektar Therapeutics had revenue of $11.18M USD in the quarter ending June 30, 2025, a decrease of -52.42%. This brings the company's revenue in the last twelve months to $74.93M, down -19.56% year-over-year. In the year 2024, Nektar Therapeutics had annual revenue of $98.43M with 9.22% growth.
Revenue (ttm)
$74.93M
Revenue Growth
-19.56%
P/S Ratio
15.71
Revenue / Employee
$1.23M
Employees
61
Market Cap
859.11M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 98.43M | 8.31M | 9.22% |
| Dec 31, 2023 | 90.12M | -1.93M | -2.10% |
| Dec 31, 2022 | 92.06M | -9.85M | -9.67% |
| Dec 31, 2021 | 101.91M | -51.01M | -33.36% |
| Dec 31, 2020 | 152.92M | 38.30M | 33.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Nektar Therapeutics News
- 8 days ago - Nektar Therapeutics (NKTR) Rises on Takeover Speculation - GuruFocus
- 8 days ago - Nektar (NKTR) Shares Surge on M&A Rumor - GuruFocus
- 8 days ago - Nektar Therapeutics gains amid takeover speculation - Seeking Alpha
- 21 days ago - Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September - The Motley Fool
- 4 weeks ago - Nektar Therapeutics (NKTR) Sees Increased Price Target from B. Riley Securities | NKTR Stock News - GuruFocus
- 5 weeks ago - Nektar Therapeutics (NKTR): BTIG Reiterates Buy Rating with $100 PT | NKTR Stock News - GuruFocus
- 5 weeks ago - Nektar Therapeutics (NKTR) Surges on Positive Drug Trial Results - GuruFocus
- 5 weeks ago - Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today - The Motley Fool